Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 5/20 | 0.43 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.43 |
| ▸ | ACE | P12821 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22044576 | 1.00 | ATM (0.45) | ATMMMEMMEL1ACEALDH1A1 | |
| SCHEMBL22044541 | 1.00 | ATM (0.45) | ATMMMEMMEL1ACEALDH1A1 | |
| SCHEMBL19479915 | 1.00 | ATM (0.45) | ATMMMEMMEL1ACEALDH1A1 | |
| SCHEMBL20529471 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL29467655 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL20529408 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL20529409 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL29467732 | 0.91 | ATM (0.42) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL24117993 | 0.90 | ALDH1A1 (0.43) | ATMALDH1A1GAAGFERAPP | |
| SCHEMBL24118107 | 0.90 | AAK1 (0.47) | ATMALDH1A1GAAGFERAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-02-11 | — | — | US | disclosed |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-20220378951-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-12-01 | — | — | US | disclosed |
| US-20210353777-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-11-18 | — | — | US | disclosed |
| US-20210346523-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-11-11 | — | — | US | disclosed |
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-10-07 | — | — | US | disclosed |
| EP-3888691-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LIKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | Hangzhou Dac Biotech Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2021-09-28 | — | — | US | disclosed |
| WO-2020258893-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2020-12-30 | — | — | WO | disclosed |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SUZHOU M-CONJ BIOTECH CO., LTD. (CN) | 2020-07-09 | — | — | US | disclosed |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2020-06-04 | — | — | US | disclosed |
| EP-2872157-B1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO LTD (CN) | 2020-01-22 | — | — | EP | disclosed |
| CN-110621673-A | Double-stranded linked cytotoxic drug conjugates | 杭州多禧生物科技有限公司 | 2019-12-27 | — | — | CN | disclosed |
| CN-110099682-A | Coupled connector, cell binding molecule-drug conjugate containing same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2019-08-06 | — | — | CN | disclosed |
| EP-3411074-A2 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | Suzhou M-conj Biotech Co., Ltd. (CN) | 2018-12-12 | — | — | EP | disclosed |
| EP-3348280-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | Hangzhou Dac Biotech Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
| US-20170157262-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157262-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | CD4, CD2, CD47 | ATM 2988/4885MME 1934/4885MMEL1 704/4885 |
| US-20210353777-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | ATM 3010/4885MME 3230/4885MMEL1 2064/4885 |
| US-20200172480-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | CD4, CD2, CD47 | ATM 2986/4885MME 2254/4885MMEL1 858/4885 |
| US-11129910-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | ATM 3010/4885MME 3230/4885MMEL1 2064/4885 |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | ATM 3010/4885MME 3230/4885MMEL1 2064/4885 |
| US-12220464-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | ATM 3010/4885MME 3230/4885MMEL1 2064/4885 |
| US-20200276261-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, TEK, BTN3A1 | ATM 4584/4885MME 465/4885MMEL1 193/4885 |
| US-20210308277-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | ATM 3906/4885MME 2501/4885MMEL1 259/4885 |
| US-20220378951-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | ATM 3010/4885MME 3230/4885MMEL1 2064/4885 |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | ATM 3010/4885MME 3230/4885MMEL1 2064/4885 |
| US-20200215206-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | ATM 3010/4885MME 3230/4885MMEL1 2064/4885 |
| US-12478695-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | ATM 3010/4885MME 3230/4885MMEL1 2064/4885 |
| US-20210346523-A1 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | SLC25A1, GCDH, FH | ATM 3010/4885MME 3230/4885MMEL1 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.